

Statute/Regulation	Statute/Regulation Purpose	Waiver benefit/explanation
28 Pa. Code § 715.16(e)	Prohibits narcotic treatment programs (NTPs –methadone clinics) from permitting a patient to receive more than a 2-week take-home supply of medication	In response to COVID-19, SAMHSA is allowing up to 28 days of take-home medications for patients on stable dosages, if the physician deems appropriate.
28 Pa. Code § 715.9(a)(4)	Requires NTPs to make a face-to-face determination before admission to treatment, for those clients who will receive buprenorphine treatment.	In response to COVID-19, SAMHSA is allowing initial evaluations for a patient who will be treated with buprenorphine to be completed via telehealth.
28 Pa. Code § 715.6(d)	Requires NTPs to have narcotic treatment physician services onsite.	In response to COVID-19, SAMHSA is allowing initial evaluations for a patient who will be treated with buprenorphine to be completed via telehealth
49 Pa. Code § 16.92(b)(1) (Department of State)	Before a patient can be prescribed any controlled substance in Pennsylvania, a person licensed to practice medicine and surgery in the commonwealth, or otherwise licensed or regulated by the State Board of Medicine, must take an initial medical history and conduct an initial physical examination, unless emergency circumstances justify otherwise.	In response to COVID-19, the Department of State suspended the initial medical history and physical examination requirement specifically for the treatment of opioid-use disorder with buprenorphine.